In addition to the commonly believed anti-inflammatory effect, according to the studies of Qin et al, Itaconate can not only inhibit the enzyme activity of ALDOA, but also modify two other key glycolytic enzymes (GAPDH and LDHA), which makes the mechanism of Itaconate participating in the process of tumor glycolysis complicated. This evidence concerns the gene ALDOA and neoplasm.